A pill to prevent HIV: Who is it for?

AIGHD Deputy Director Cate Hankins argues in Expert Review of Pharmacoeconomics & Outcomes Research that HIV pre-exposure prophylaxis or PrEP may be a workable option over short- to medium-term risky periods for people who are unable to use proven HIV prevention methods such as condoms and sterile injecting equipment. Providers can play a critical role in helping people decide for themselves whether PrEP is a good choice for them, given their sexual and injecting practices and the HIV prevention measures they are able to use in the current context of their lives, whether they would be able to take it regularly, and what support they might need. PrEP is most cost-effective for those at highest risk of HIV and when it is part of combination prevention addressing both immediate risks and underlying vulnerabilities. Read more here